戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ied the function of liver PPAR gamma in both lipoatrophic A-ZIP/F-1 (AZIP) and wild type mice.
2 the beta3 effects studied were absent in the lipoatrophic A-ZIP/F-1 mice, including the effects on no
3                                           In lipoatrophic A-ZIP/F-1 mice, transplantation of normal a
4                                           In lipoatrophic A-ZIP/F1 'fatless' mice, which are genetica
5 group, raising the possibility of a specific lipoatrophic activity for leptin.
6       These alterations result in a cellular lipoatrophic condition that compromises uterine tissue i
7 suggests a mouse model for the human disease lipoatrophic diabetes (Seip-Berardinelli syndrome), indi
8 are rescued from neonatal death, but develop lipoatrophic diabetes and die prematurely.
9                         NASH associated with lipoatrophic diabetes can recur after liver transplantat
10                                              Lipoatrophic diabetes is an insulin resistance syndrome
11 le of PPARalpha agonists in the treatment of lipoatrophic diabetes is warranted.
12 article describes the first reported case of lipoatrophic diabetes with NASH leading to liver failure
13                                           In lipoatrophic diabetes, a lack of fat is associated with
14 ikingly resembles that of humans with severe lipoatrophic diabetes, including the lack of fat, marked
15      However, in contrast to other models of lipoatrophic diabetes, there was no accumulation of fat
16 ribute to the insulin resistance observed in lipoatrophic diabetes.
17 is, and fibrosis that can be associated with lipoatrophic diabetes.
18 troglitazone may have therapeutic benefit in lipoatrophic diabetes.
19 trol and increased body fat in patients with lipoatrophic diabetes.
20  A-ZIP/F-1 mice, which have a severe form of lipoatrophic diabetes.
21 -) double knockout mouse as a novel model of lipoatrophic diabetes.
22 43 in the A-ZIP/F-1 mouse, a model of severe lipoatrophic diabetes.
23 lin resistance and reduces hyperlipidemia in lipoatrophic humans.
24 tin cotreatment normalizes insulin action in lipoatrophic insulin-resistant animals.
25 ast, rosiglitazone remained effective in non-lipoatrophic mice lacking liver PPAR gamma, suggesting t
26  metabolic phenotype of the A-ZIP/F-1 (AZIP) lipoatrophic mouse is different depending on its genetic
27 -n sterol response element binding protein 1 lipoatrophic mouse.
28 le explanation for both the diabetic and the lipoatrophic phenotype in Ncb5or(-/-) mice.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。